Latest news with #Divi's
&w=3840&q=100)
Business Standard
19-05-2025
- Business
- Business Standard
Strong growth seen for Divi's Laboratories, but upside capped by valuations
Divi's posted a 12 per cent growth in revenues over the year-ago quarter. Although revenue growth has moderated after four consecutive quarters of top line growth in the 18-25 per cent range Ram Prasad Sahu Listen to This Article The stock of contract development and manufacturing organisation (CDMO) Divi's Laboratories was among the top gainers in the BSE 100 index on Monday. It rose 4.81 per cent as fourth-quarter revenues beat estimates across key segments, while margins hit multi-quarter highs. The management has guided for double-digit growth for 2025–26 (FY26), which, coupled with stronger momentum from China+1 and the commercialisation of the blood sugar control drug glucagon-like peptide-1 (GLP-1), will act as key triggers. Brokerages, however, believe upsides are limited as valuations have turned expensive. Divi's posted a 12 per cent growth in revenues over the year-ago quarter. Although
Business Upturn
19-05-2025
- Business
- Business Upturn
Divi's Laboratories shares jump nearly 3% as Q4 revenue rises 12% YoY to Rs 2,585 crore
By Aman Shukla Published on May 19, 2025, 09:20 IST Divi's Laboratories Limited shares jumped nearly 3% in morning trade following the release of strong Q4 FY25 results. As of 9:19 AM, the shares were trading 2.89% higher at Rs 6,459.50. The company reported a 23% year-on-year (YoY) rise in consolidated net profit to ₹662 crore for the quarter ended March 31, 2025, compared to ₹538 crore in Q4 FY24. The impressive growth was supported by higher sales and better operational efficiency. Revenue from operations rose 12% YoY to ₹2,585 crore, up from ₹2,303 crore in the same period last year. Total income for the quarter stood at ₹2,671 crore, compared to ₹2,382 crore in Q4 FY24. The company's EBITDA increased to ₹869 crore from ₹808 crore, with a stable EBITDA margin of 32.5%. Despite a rise in total expenses to ₹1,807 crore, driven by higher material and employee costs, Divi's posted a profit before tax of ₹864 crore—up from ₹713 crore a year ago. For the full financial year FY25, Divi's Laboratories reported a net profit of ₹2,191 crore, marking a robust 37% increase from ₹1,600 crore in FY24. Total income for the year rose to ₹9,712 crore from ₹8,184 crore. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Time of India
25-04-2025
- Business
- Time of India
Hot Stocks: 3 stocks that may give returns between 13-43%
A look at some of the latest stock recommendations by analysts . These stocks are expected to return between 13% and 43% as per analyst price targets . DIVI'S LABORATORIES by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Boria: The price (& size) of these hearing aids might surprise you Learn More Undo BROKERAGE: CITI Price Target: Rs 7,050 CMP: Rs 6,216 | Upside: 13% Play Video Pause Skip Backward Skip Forward Unmute Current Time 0:00 / Duration 0:00 Loaded : 0% 0:00 Stream Type LIVE Seek to live, currently behind live LIVE Remaining Time - 0:00 1x Playback Rate Chapters Chapters Descriptions descriptions off , selected Captions captions settings , opens captions settings dialog captions off , selected Audio Track Picture-in-Picture Fullscreen This is a modal window. Beginning of dialog window. Escape will cancel and close the window. Text Color White Black Red Green Blue Yellow Magenta Cyan Opacity Opaque Semi-Transparent Text Background Color Black White Red Green Blue Yellow Magenta Cyan Opacity Opaque Semi-Transparent Transparent Caption Area Background Color Black White Red Green Blue Yellow Magenta Cyan Opacity Transparent Semi-Transparent Opaque Font Size 50% 75% 100% 125% 150% 175% 200% 300% 400% Text Edge Style None Raised Depressed Uniform Drop shadow Font Family Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual Script Small Caps Reset restore all settings to the default values Done Close Modal Dialog End of dialog window. Orforglipron, Eli Lilly's oral diabetes drug, next addition in Divi's pipeline Potential to become primary supplier Company has announced $170-million capex, which Citi believes is primarily for GLP-1—medication to manage Type 2 diabetes and obesity Divi's could be a key player for Eli Lilly's next weight loss product—Retatrutide DEVYANI INTERNATIONAL BROKERAGE: BERNSTEIN Price Target: Rs 220 CMP: Rs 179 | Upside: 23% Reiterate positive view after acquiring majority stake in unlisted Sky Gate Hospitality, which owns Biryani By Kilo and other cloud kitchens Value accretive for Devyani as deal done at 2-2.5 times sales QSR (Quick Service Restaurant) chains at 4-6.6 times sales FY25 and FY26 earnings to be volatile because of M&A and growth moves Live Events ANANT RAJ BROKERAGE: NOMURA Price Target: Rs 700 CMP: Rs 488 | Upside: 43% Reiterate Buy rating but cut price target from Rs 750 to Rs 700 citing a more conservative stance on its data centre unit Company's 307 Mega Watt Data Centre target will be reached by FY32-33 as against earlier expectations of FY31 Valuations still attractive as earnings per share estimated to grow over 40% on a compounded basis over FY26-27
